Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer

Molecular Imaging and Biology

Volumn 18, Issue 3, 2016, Pages 402-410

  Nedrow, Jessie R ^a   Latoche, Joseph D ^a   Day, Kathryn E ^a   Modi, Jalpa ^a   Ganguly, Tanushree ^d   Zeng, Dexing ^a   Kurland, Brenda F ^c   Berkman, Clifford E ^d   Anderson, Carolyn J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b University of Pittsburgh   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Copper 64; Irreversible inhibitor; PET; Phosphoramidate; PSMA

Indexed keywords

COPPER 64; CTT 1297; PHOSPHORAMIDIC ACID DERIVATIVE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; AMIDE; COPPER; PHOSPHORAMIDIC ACID; PHOSPHORIC ACID; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CLICK CHEMISTRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; LNCAP CELL LINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG SCREENING; ENDOCYTOSIS; METABOLISM; NUDE MOUSE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; PROSTATE TUMOR; SYNTHESIS; TISSUE DISTRIBUTION;

AMIDES; ANIMALS; BLOTTING, WESTERN; COPPER RADIOISOTOPES; ENDOCYTOSIS; MALE; MICE, NUDE; PHOSPHORIC ACIDS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946763408     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-015-0908-7     Document Type: Article

References (43)

1. Chu TC, Shieh F, Lavery LA et al (2006) Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates. Biosens Bioelectron 21:1859–1866
2. Farokhzad OC, Khademhosseini A, Jon S et al (2005) Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal Chem 77:5453–5459
3. Guilarte TR, McGlothan JL, Foss CA et al (2005) Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography. Neurosci Lett 387(3):141–144
4. Humblet V, Lapidus R, Williams LR et al (2005) High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging 4:448–462
5. Milowsky MI, Nanus DM, Kostakoglu L et al (2007) Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 25:540–547
6. Tsukamoto T, Wozniak KM, Slusher BS (2007) Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today 12:767–776
7. Lapi SE, Wahnishe H, Pham D et al (2009) Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med 50:2042–2048
8. Nedrow-Byers JR, Jabbes M, Jewett C et al (2012) A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent. Prostate 72:904–912
9. Banerjee SR, Pullambhatla M, Foss CA et al (2014) (6)(4)Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem 57:2657–2669
10. Lu J, Celis E (2002) Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 62(20):5807–5812
11. Liu T, Wu LY, Berkman CE (2010) Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption. Cancer Lett 296:106–112
12. Bander NH, Milowsky MI, Nanus DM et al (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23:4591–4601
13. Milowsky MI, Nanus DM, Kostakoglu L et al (2004) Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22:2522–2531
14. Bacich DJ, Pinto JT, Tong WP, Heston WD (2001) Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 12(2):117–123
15. Zhang L, Wang CY, Yang R et al (2008) Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis. Urol Oncol 26:634–640
16. Perner S, Hofer MD, Kim R et al (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696–701
17. Bradford TJ, Tomlins SA, Wang X, Chinnaiyan AM (2006) Molecular markers of prostate cancer. Urol Oncol 24:538–551
18. Evans MJ, Smith-Jones PM, Wongvipat J et al (2011) Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 108:9578–9582
19. Hillier SM, Kern AM, Maresca KP et al (2011) 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med 52:1087–1093
20. Baum EM, Ernestis, MC, Know HD, et al (2010) Nuclides and isotopes chart of the nuclides. In: Edward Baum. Marine B (ed) Propulsion Corporation, pp 54-55
21. Rockey WM, Huang L, Kloepping KC et al (2011) Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging. Bioorg Med Chem 19:4080–4090
22. Hao G, Kumar A, Dobin T et al (2013) A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen. Mol Pharm 10:2975–2985
23. Liu T, Wu LY, Kazak M, Berkman CE (2008) Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate 68:955–964
24. Nedrow-Byers JR, Jabbes, M., Jewett, C., et al (2011) A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent. The Prostate
25. Nedrow-Byers JR, Moore AL, Ganguly T et al (2013) PSMA-targeted SPECT agents: mode of binding effect on in vitro performance. Prostate 73:355–362
26. Zeng D, Ouyang Q, Cai Z et al (2014) New cross-bridged cyclam derivative CB-TE1K1P, an improved bifunctional chelator for copper radionuclides. Chem Commun (Camb) 50:43–45
27. Sprague JE, Peng Y, Sun X et al (2004) Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res 10:8674–8682
28. 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors. J Nucl Med 49:1819–1827
29. Anderson CJ, Jones LA, Bass LA et al (1998) Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J Nucl Med 39:1944–1951
30. Aggarwal S, Ricklis RM, Williams SA, Denmeade SR (2006) Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human. Prostate 66:903–910
31. Gregor PD, Wolchok JD, Turaga V et al (2005) Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer 116:415–421
32. Chen Y, Foss CA, Byun Y et al (2008) Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem 51:7933–7943
33. Kularatne SA, Wang K, Santhapuram HK, Low PS (2009) Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm 6:780–789
34. Weiner RE, Thakur ML (2005) Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs: Clin Immunother Biopharm Gene Ther 19:145–163
35. Weiner RE, Thakur ML (2002) Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 57:749–763
36. Foss CA, Mease RC, Fan H et al (2005) Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 11:4022–4028
37. Lesche R, Kettschau G, Gromov AV et al (2014) Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging 41:89–101
38. Liu AY, Brubaker KD, Goo YA et al (2004) Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines. Prostate 60:98–108
39. Liu H, Rajasekaran AK, Moy P et al (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58:4055–4060
40. Ganguly T, Dannoon S, Hopkins MR, et al (2015) A high-affinity [F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Nucl Med Biol
41. Banerjee SR, Foss CA, Castanares M et al (2008) Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 51:4504–4517
42. Ray Banerjee S, Pullambhatla M, Foss CA et al (2013) Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). J Med Chem 56:6108–6121
43. Muller C, Struthers H, Winiger C et al (2013) DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice. J Nucl Med 54:124–131